Clinical Trial: BIIB017 (PEGylated interferon beta-1a) - ADVANCE
| Description | |
|---|---|
| A multicenter, randomized, double-blinded, parallel-group, placebo-controlled study to evaluate the efficacy and safety of PEGylated interferon beta-1a in subjects with relapsing MS | |
| Institution/Location | Contact Information |
| Multicenter Florida Georgia Kentucky North Carolina Ohio Tennessee Texas | ADVANCEStudy@biogenidec.com |
Treatment mode of action: To affect immune function
Institution(s): Multicenter, nationwide
Type of MS: Relapsing
Number of Subjects: 1260
Funding: Biogen Idec